<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175120</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-4166</org_study_id>
    <secondary_id>U1111-1154-6732</secondary_id>
    <secondary_id>CTR20060909</secondary_id>
    <nct_id>NCT03175120</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)</brief_title>
  <acronym>DUAL™ II China</acronym>
  <official_title>A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The aim of this trial is to confirm the superiority of
      insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese
      subjects with type 2 diabetes mellitus after 26 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">May 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (glycosylated haemoglobin)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in kg and/or %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent severe or blood glucose confirmed hypoglycaemic episodes</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>Week 26</time_frame>
    <description>Dose in Units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0%</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0% and change in body weight below or equal to zero</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.5% and change in body weight below or equal to zero</measure>
    <time_frame>Week 26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0% without severe or blood glucose (BG) confirmed hypoglycaemic episodes during the last 12 weeks of treatment</measure>
    <time_frame>Weeks 14-26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.5% without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment</measure>
    <time_frame>Weeks 14-26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below 7.0% and change in body weight below or equal to zero and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment</measure>
    <time_frame>Weeks 14-26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.5% and change in body weight below or equal to zero and without severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment</measure>
    <time_frame>Weeks 14-26</time_frame>
    <description>Proportion of subjects - fulfilling all criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean of the 9-point profile</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function, quantified by homeostatic model assessment (HOMA-β)</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid profile</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent nocturnal severe or blood glucose (BG) confirmed hypoglycaemic episodes</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent hypoglycaemic episodes according to ADA definition</measure>
    <time_frame>Weeks 0-26</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean post prandial increment (from before meal to 90 min after for breakfast, lunch and dinner). The mean increment over all meals will be derived as the mean of all available meal increments. Fasting C-peptide</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean post prandial increment (from before meal to 90 min after for breakfast, lunch and dinner). The mean increment over all meals will be derived as the mean of all available meal increments. Fasting glucagon</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean post prandial increment (from before meal to 90 min after for breakfast, lunch and dinner). The mean increment over all meals will be derived as the mean of all available meal increments. Fasting insulin</measure>
    <time_frame>Week 26</time_frame>
    <description>Measured in µU/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin degludec/liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin degludec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec/liraglutide</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.</description>
    <arm_group_label>Insulin degludec/liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.</description>
    <arm_group_label>Insulin degludec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Informed consent obtained before any trial-related activities. Trial-related activities are
        any procedures that are carried out as part of the trial, including procedures to determine
        suitability for the trial

          -  Male or female, age at least 18 years at the time of signing inform consent

          -  Type 2 diabetes mellitus (clinically diagnosed)

          -  HbA1c (glycosylated haemoglobin) above or equal to 7.5% by central laboratory
             analysis, with the aim of a median of 8.5%. When approximately 50% of the randomised
             subjects have an HbA1c above 8.5%, the remaining subjects randomised must have an
             HbA1c below or equal to 8.5% or when approximately 50% of the subjects randomised have
             an HbA1c below or equal to 8.5%, the remaining subjects randomised must have an HbA1c
             above 8.5%

          -  Current treatment for at least 90 calendar days prior to screening with basal insulin
             plus metformin plus/minus α-glucosidase inhibitors, sulphonylureas, glinides or
             thiazolidinediones. Subjects should be on a stable dose for at least 60 calendar days
             prior to screening of:

        Basal insulin 20-50 units (U)/day (both inclusive) ( Individual fluctuations of plus/minus
        5U during the 60 day period prior to the day of screening are acceptable.) on the day of
        screening in combination with:

          -  Metformin (above or equal to 1500 mg or max tolerated dose) or

          -  Metformin (above or equal to 1500 mg or max tolerated dose) and sulphonylureas (above
             or equal to half of the max approved dose according to local label) or

          -  Metformin (above or equal to 1500 mg or max tolerated dose) and glinide (at least half
             of the max approved dose according to local label) or

          -  Metformin (above or equal to 1500 mg or max tolerated dose) and α-glucosidase
             inhibitors (AGI) (at least half of the max approved dose according to local label) or

          -  Metformin (above or equal to 1500 mg or max tolerated dose) and thiazolidinediones (at
             least half of the max approved dose according to local label)

          -  Body mass index (BMI) above or equal to 24 kg/m^2

        Exclusion Criteria:

        Current use of any antidiabetic drug (except for basal insulin, metformin, α-glucosidase
        inhibitors, sulphonylureas, glinides or thiazolidinediones) or anticipated change in
        concomitant medication, that in the investigator´s opinion could interfere with glucose
        level (e.g. systemic corticosteroids)

          -  Treatment with glucagon like peptide -1 receptor agonists, or dipeptidyl-peptidase-4
             inhibitors or insulin (except for basal insulin) within 90 days prior to Visit 1

          -  Impaired liver function defined as alanine aminotransferase above or equal to 2.5
             times upper normal range

          -  Impaired renal function defined as serum-creatinine above or equal to 133 μmol/L for
             males and above or equal to 125 μmol/L for females, or as defined according to local
             contraindications for metformin Screening calcitonin above or equal to 50 ng/L

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia type 2 (MEN2)

          -  Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis
             of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the
             last 12 months prior to screening and/or planned coronary, carotid or peripheral
             artery revascularisation procedures

          -  Severe uncontrolled treated or untreated hypertension (systolic blood pressure above
             or equal to 180 mm Hg or diastolic blood pressure above or equal to 100 mm Hg)

          -  Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment

          -  History of pancreatitis (acute or chronic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>ChongQing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <zip>053000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yueyang</city>
        <state>Hunan</state>
        <zip>414000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Huhehaote</city>
        <state>Inner Mongolia</state>
        <zip>010020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Huhhot</city>
        <state>Inner Mongolia</state>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

